209 related articles for article (PubMed ID: 31233227)
1. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Kranzbühler B; Salemi S; Umbricht CA; Müller C; Burger IA; Sulser T; Eberli D
Prostate; 2018 Jul; 78(10):758-765. PubMed ID: 29633296
[TBL] [Abstract][Full Text] [Related]
3. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
[TBL] [Abstract][Full Text] [Related]
4. Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro.
Kuzmanov A; Salemi S; Schmid FA; Burger IA; Eberli D; Kranzbühler B
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569712
[TBL] [Abstract][Full Text] [Related]
5. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract][Full Text] [Related]
6. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
7. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
10. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
[TBL] [Abstract][Full Text] [Related]
11. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
14. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [
Müller M; Lucaroni L; Favalli N; Bassi G; Neri D; Cazzamalli S; Oehler S
J Med Chem; 2024 May; 67(10):8247-8260. PubMed ID: 38716576
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
20. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]